As businesses reopen, it's crucial we wear masks, safely distance

In a perspective piece published in the journal Science, UC San Diego experts describe in detail the growing evidence that SARS-CoV-2, the novel coronavirus that causes COVID-19, can be spread by asymptomatic people via aerosols - a reality that deeply underscores the ongoing importance of regular widespread testing, wearing masks and physical distancing to reduce the spread of the virus.

Highlights

Asymptomatic people spread virus in aerosols. Mounting evidence suggests that SARS-CoV-2 is silently spread in aerosols exhaled by contagious infected persons displaying no symptoms. A recent study estimated that a single minute of loud speaking might generate between 1,000-100,000 virion-containing aerosols or virus particles suspended in the air. Due to their small size, aerosols can remain airborne for hours and travel long distances. Small, virus-containing aerosols can also penetrate more deeply into the lungs, bypassing the immune system, which can lead to more severe cases of COVID-19.

Traditional measures target droplets, not buoyant aerosols. Traditional respiratory disease controls based on physical spacing are designed to reduce transmission from large droplets produced in the sneezes and coughs of infected individuals. However, a large fraction of the spread of COVID-19 appears to be occurring through airborne transmission of smaller aerosols produced by infected but asymptomatic individuals during breathing and speaking. Droplets settle to surfaces within six feet and spread via contact. Contrarily, infectious aerosols can accumulate in indoor, uncirculating air for hours, where they can be more easily inhaled deeply into the lungs.

Infectious aerosols can travel further than six feet. Given how little is known about the airborne behavior of infectious aerosols, it's difficult to define a safe distance for physical distancing. However, a six-foot perimeter indoors without a mask is likely not enough if an asymptomatic person is actively shedding the virus, researchers say. A good comparison is exhaled smoke: The distance from a smoker at which you can smell smoke indicates the distance at which you might also inhale infectious aerosols. Many factors affect aerosol spread indoors and outdoors, such as air flow and ventilation, number of people in the space, time of exposure , sunlight, temperature and humidity.

Masks are essential. Properly fitted masks provide a critical physical barrier, reducing the number of infectious viruses in the exhaled breath of asymptomatic individuals. Countries that have been most effective in limiting the spread of COVID-19 have implemented universal masking. For example, Taiwan (population 24 million), where masking orders were universal and quickly enacted, did not implement a lockdown during the pandemic; yet it maintained a low incidence of approximately 441 cases and 7 deaths. By contrast, New York State (population 20 million) has had more than 353,000 COVID-19 cases and 24,000 deaths.

Kimberly A Prather, Chia C Wang, Robert T Schooley.
Reducing transmission of SARS-CoV-2.
Science, 2020. doi: 10.1126/science.abc6197.

Most Popular Now

Novartis research shows technology talent increasi…

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing res...

GSK COVID-19 vaccine development collaboration wit…

GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiati...

Lilly begins world's first study of a potential CO…

Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This inve...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

Sanofi and Translate Bio expand collaboration to d…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to ...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Bayer supports "The Challenge Initiative…

Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...